Editorial Board
10 Nov 2024, 1 p.m.
Publication date: November 2024Source: Pancreatology, Volume 24, Issue 7Author(s):
Contents |
Thursday 01st December 2022
Parallel Subspecialty Sessions | |
PSGBI | |
08.50 - 09.00 | Welcome |
09.00 - 09.15 | Opening Address |
09.15 - 19.30 | How does a large NHS Trust enhance a small expensive regional service? |
Pancreatic Cancer Services | |
09.30 - 09.45 | What actually happens to our pancreatic cancer patients - RICHOCET and CONTACT studies |
09.45 - 10.00 | Developing pathways to improve pancreatic cancer management |
10.00 - 10.15 | What do our patients want from a pancreatic cancer serivce? |
10.15 - 10.30 | Setting up and maintaining a local pancreatic cancer support service - PANPALS |
10.30 to 11:00 | |
11:00 to 12.30 | Current approaches in pancreatic cancer |
11.00 - 11.15 | At risk groups to screen for pancreatic cancer |
11.15 - 11.30 | Precision Oncoclogy in Pancreatic Cancer |
11.30 - 11.45 | What is the current evidence for neoadjuvant therapy in PDAC ? |
11.45 - 12.00 | Immunotherapy in PDAC |
12.00 - 12.15 | Should we perform either Arterial and venous resections after neoadjuvant therapy ? |
12.15 - 12.30 | Can we effectively assess surgical performance at Whipples ? |
12.30 to 13.30 | LUNCH |
12.30 to 13:30 | |
13.30 to 14.20 | LORD SMITH MEDAL ORAL PRESENTATIONS |
1. Improving risk stratification of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas, the results of the two-centre transatlantic study. 2. A retrospective cohort study investigating the progression of sarcopenia and its impact on outcomes in patients with pancreatic cancer undergoing neoadjuvant chemotherapy 3. Current Practice and Opinion Regarding Postoperative Feeding Regimens in Pancreatoduodenectomy Patients: Basis for a National Trial? 4. Evaluating aspirin & metformin in relation to a prognostic role. Analysis of ESPAC 4 randomised trial of adjuvant gemcitabine versus gemcitabine plus capectabine in resected pancreatic cancer patients 5. Sarcopenic obesity is common in patients admitted to critical care with severe acute pancreatitis and is a strong predictor of mortality. |
|
14.20 - 15.10 | Local Control of Pancreatic Cancer |
14.20 - 14.32 | LAP-PIE trial |
14.32 - 14.44 | Margin accentuation using irreversible electroporation |
14.44 - 14.56 | EUS-guided ablation therapy |
14.56 - 15.10 | Intra- operative Radiotherapy in PDAC |
15.10 - 15.40 | |
15.40 - 17.30 | Update on acute pancreatitis |
15:30 - 15:40 | A patients perspective on severe acute pancreatitis |
15:40 - 15.55 | Relation of early severity and necrotizing pancreatitis, critical illness trajectories in acute pancreatitis |
15.55 - 16.10 | PANC study update |
16.10 - 16.25 | Pancreatitis priority setting partnership |
16.25 - 16.40 | Optimal timing of interventions in necrotizing pancreatitis (Pointer study) |
16.40 - 16.55 | Oral feeding intolerance. Introduction of enteral nutrition, appropriate timing and method |
16.55 - 17.10 | Optimising pain control in acute pancreatitis |
17.00 - 17.15 | Psychosocial impact of nectrotizing pancreatitis |
|
19:00 Pre dinner drinks followed by Gala dinner @19:30 |
Register for the meeting here |
|
|
The NHpbNG will join the other delegates for the 1st session in the morning
08.50 – 09.00 Welcome
09.00 – 09.15 How does the pancreatic community effectively lobby?
09.15 – 09.30 How does a large NHS Trust enhance a small expensive regional service?
09.30 – 09.45 What actually happens to Pancreatic Cancer patients – RICHOCET and CONTACT Studies
09.45 – 10.00 Developing pathways to improve pancreatic cancer management
10.00 – 10.15 What do our patients want from a pancreatic cancer service?
10.15-10.30 Setting up and maintaining a local pancreatic cancer support service - PANPALS
10.30 – 11.00 Coffee Break
11.00 – 11.05 Welcome to the morning session – Phil
11.05 – 1130 – National Hpb Nurse Group update; Lynne McCallum Pancreatic Cancer Nurse Specialist PCUK
1130 – 1230 CNS Roles during COVID: Impact and Moving Forward Dr Anna Taylor Leeds and York Partnership NHS Foundation Trust
12.30 – 13.30 Lunch
13.30 – 13.35 Welcome to the afternoon session – Claire P
13.35 – 13.55 Tissue is the Issue; Professor Juan Valle Consultant Oncologist Manchester
13.55 – 14.15 Our Pancreatic Unit during COVID 19; Phil Whelan Macmillan Pancreatic CNS Liverpool University Foundation Hospital Trust
14.15 – 14.30 Development of a national Best Practice Timed Pathway (BPTP) for HPB cancers; Peter De Rosa, Policy and Health Improvement Manager, Pancreatic Cancer UK London
14.30 – 14.50 Pancreas RDS, the challenges and successes; Vicki Stevenson-Hornby Specialist Nurse for the Pancreas and HPB Rapid Diagnostic Service Blackburn
14.50- 15.10 The CNS role in Personalised Care; Carolynne Hardy UGi/HPB CNS and Personalised Cancer Care Manager South Tyneside & Sunderland NHS Foundation Trust
1510 – 1525 – Comfort break
15.25 - 15.45 “A Pancreatic Tale” a story of survival; Barb Ashall Lead Upper Gastrointestinal Cancer Nurse Specialist St Helens & Knowsley Hospitals
15.45- 16.05 Radiotherapy, SABR and Proton Beam; update for practice; Dr Ganesh Radhakrishna Consultant Clinical Oncologist Manchester
16.05- 16.25 Monitoring the HPB patient experience; Claire Pearce, Lead Macmillan HPB CN Clinical Nurse University Hospital Coventry and Warwickshire
1625-1645 Supportive care research: Pancreatic Cancer UK's vision & ambitions Chris Macdonald, Head of Research PCUK & Charlotte Lynch, Research Strategy Manager PCUK
1645-1700 Closing of meeting and travel reimbursement Lynne